OTTAWA, Jan. 5, 2012 /CNW/ - In the past ten years, 93 radiation
oncology clinicians and researchers from coast-to-coast have made
significant advances in the treatment of prostate cancer, thanks to the
critical partnership between the Canadian Association of Radiation
Oncology (CARO-ACRO) and Abbott, the global health care company, which
annually provides $200,000 in funding for the ACURA Uro-Oncologic
An independent CARO-ACRO selection committee evaluates 30 to 40 research
proposals submitted, and chooses up to ten recipients each year. The
complete list of studies funded from 2001 through 2011 is found at: http://www.caroacro.ca/Committees_and_Programs/Programs/ACURA.htm.
According to Dr. Andrea Bezjak, CARO-ACRO President, "The ACURA Award
program provides a highly valued source of seed funding for basic
science, translational, clinical and population-based prostate cancer
research. Canadians with prostate cancer, who are being treated with
radiation, experience the direct benefits from advances in the
understanding and improved management of the disease. At CARO-ACRO, our
goal is to continually improve our patient outcomes and quality of
life, as well as our health services."
Dr. Fabio Cury, Radiation Oncologist, Chair, 2012 ACURA Advisory Group,
explains the importance of the awards, "The ACURA awards help Canadian
radiation oncologists to significantly improve care for prostate cancer
patients, by translating novel ideas into clinical practice through
excellent research. Past recipients were able to start or establish new
research lines, testing unique radiation treatment ideas including:
biomarkers, imaging, brachytherapy, radiosurgery, radiosensitizers,
among many others, resulting in continual treatment improvements."
"We are very pleased to be a long standing supporter of research in
oncology. Over the last decade of our involvement with this program we
have seen many amazing projects come to light. Our goal is to
encourage our talented researchers to continue to find ways of
improving the lives of those with cancer," adds Felipe Pastrana,
General Manager, Abbott Canada.
About the Canadian Association of Radiation Oncology
Canadian Association of Radiation Oncology (CARO) - Association
canadienne de radio-oncologie (ACRO) is a not-for-profit association
with the mandate to represent and support its membership nationally and
internationally, through the promotion of high standards of patient
care in the practice of radiation oncology, support of excellence in
professional standards, and promotion of radiation oncology research
CARO is a partner with other disciplines in seeking to improve outcomes
for cancer patients, and provides a consultative authority to oncology
related agencies, academic institutions, and to the public in all
matters pertaining to radiotherapy and oncology in Canada. For further
Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals
and medical products, including nutritionals, devices and diagnostics.
The company employs nearly 90,000 people and markets its products in
more than 130 countries. Abbott has been operating in Canada since 1931
and its Canadian operations are headquartered in Montreal, Quebec.
Abbott Canada employs more than 2,000 people. Abbott's news releases
and other information are available on the company's web sites at www.abbott.ca and www.abbott.com.
SOURCE Canadian Association of Radiation Oncology
For further information:
CARO-ACRO Contact: J. McLarty, email@example.com or (604) 740-5839
Abbott Canada Contact: E. Murphy, firstname.lastname@example.org or (514) 832-7788